A new blood test developed by researchers at the University of Cambridge is raising hopes of a long-awaited breakthrough in prostate cancer detection, offering a level of accuracy that could transform how the disease is screened, diagnosed, and treated across the UK. The research suggests it may finally overcome the limitations of the widely used prostate-specific antigen test, long criticised for being too unreliable for population-wide screening.
Prostate cancer is the most common cancer affecting men in the UK and claims around 12,000 lives annually. Despite this burden, it remains the only major cancer without a national NHS screening programme. The absence of routine screening has been driven not by a lack of concern, but by fears that existing tests do more harm than good when applied to large populations.
The PSA blood test, currently the main diagnostic tool, can identify prostate cancer in men who present with symptoms. However, it has significant shortcomings. It can fail to detect aggressive cancers while also flagging slow-growing tumours that may never threaten a patient’s life. This has resulted in false reassurance for some men and unnecessary anxiety, biopsies, and treatments for others. More detail on the strengths and weaknesses of PSA testing can be found in this explainer on the PSA test and prostate cancer.
The Cambridge-led research aims to change this balance. Scientists are developing a blood test that looks not just for signs of cancer, but for biological signals that indicate how aggressive the disease is and whether it is likely to require treatment. The goal is to give doctors and patients clearer, earlier answers, reducing guesswork and invasive procedures.
At the heart of the test is the detection of DNA methylation markers, fragments of genetic material released into the bloodstream by cancer cells. These markers act as a molecular fingerprint, revealing whether cancer is present and how it behaves. By analysing thousands of these signals simultaneously, the test can pick up patterns that were previously too faint to measure reliably.
Dr Harveer Dev, lead researcher at the University of Cambridge’s Early Cancer Institute, has said the team is seeing “really promising results” despite the test still being in development. He argues that current diagnostic pathways lack the right combination of tools to deliver accurate, patient-centred care, a gap this new test is designed to fill.
One of the most significant advantages of the approach is its ability to distinguish between lethal and non-lethal cancers. For decades, clinicians have struggled with overdiagnosis, where men are treated for cancers that would never have affected their health or life expectancy. This has led to avoidable side effects such as incontinence and impotence. A test that can reliably assess cancer aggressiveness could dramatically reduce these harms.
The research draws on blood samples from more than 1,000 men from Europe and Africa, many of which were collected up to 30 years ago. Because researchers know which donors later developed prostate cancer, they can assess whether the test accurately detects early molecular warning signs long before symptoms appear. This long-term follow-up strengthens confidence in the findings and their relevance to real-world screening.
The potential policy implications are substantial. At present, men without symptoms can request a PSA test from their GP, but family doctors are not allowed to proactively offer screening. The UK National Screening Committee has repeatedly concluded that PSA testing is too unreliable for general screening, recommending it only for men with specific gene variants. Coverage of this decision and the controversy surrounding it is available via this report on UK screening policy.
Campaigners, including those supported by The Telegraph, have argued for targeted screening of high-risk groups such as black men and those with a family history of prostate cancer. However, concerns over test accuracy have remained a barrier. A more precise blood test could remove that obstacle, opening the door to a national screening programme that balances early detection with patient safety.
Health Secretary Wes Streeting has indicated that the debate over prostate cancer screening is far from settled, pledging to revisit the arguments as new evidence emerges. Should the Cambridge test prove effective in clinical trials, it would give policymakers a powerful new option at a time when public pressure for reform is growing.
Importantly, researchers stress that the new blood test is not intended to replace PSA testing entirely. Instead, it would act as an additional layer of analysis, helping doctors decide which patients truly need biopsies or immediate treatment. For men with raised PSA levels, it could provide reassurance or urgency without the need for invasive procedures.
Dr Naomi Elster, director of research at Prostate Cancer Research, which is supporting the study, has described the test as a “very clever” tool that can show whether key genes have been switched on or off. She emphasises that this information is critical to ensuring patients receive the right treatment at the right time, rather than a one-size-fits-all approach.
Beyond clinical accuracy, the simplicity of a blood-based test could make nationwide rollout far easier than imaging-heavy or invasive diagnostics. Blood tests are familiar, relatively low-cost, and generally accepted by patients, preserving dignity while delivering clarity. For healthcare systems under strain, this ease of use is a major advantage.
The research team plans to begin clinical trials involving UK patients within the next 18 to 24 months. Early trials will focus on determining where the test fits best in the diagnostic pathway, whether before or after PSA screening. These decisions will shape how the technology could be integrated into NHS practice if approved.
Internationally, the implications extend beyond the UK. Prostate cancer is a leading cause of cancer death among men worldwide, and screening controversies are not unique to Britain. A reliable blood test that differentiates aggressive disease from indolent cases could influence global guidelines and standards of care, particularly in regions with limited access to advanced imaging.
From a patient perspective, the promise is simple but profound: fewer missed cancers, fewer unnecessary treatments, and clearer answers at an earlier stage. For families affected by prostate cancer, the development represents hope that future diagnoses will be less traumatic and more precise.
As research continues, organisations such as Prostate Cancer Research and academic centres like the University of Cambridge will play a central role in translating laboratory advances into clinical reality. Readers interested in related health innovations and policy debates can explore more coverage at World at Net’s health section and broader reporting on cancer research from trusted outlets such as the NHS and Prostate Cancer UK.
If the results seen so far are confirmed in trials, the Cambridge blood test could mark a turning point in one of men’s most persistent health challenges. After decades of uncertainty, prostate cancer screening may finally be on the brink of becoming both effective and fair, aligning early detection with informed, personalised care.
0 Comments